Soulillou J P, Carpenter C B, d'Apice A J, Strom T B
J Exp Med. 1976 Feb 1;143(2):405-21. doi: 10.1084/jem.143.2.405.
The ability of a hyperimmune Lew anti-BN serum (HIS) to induce enhancement of (Lew/BN)F1 kidneys transplanted into Lew recipients was compared to that of the same antiserum that had been depleted of hemagglutinating anti-Ag-B antibodies by absorption with Brown-Norway (BN) RBC-absorbed sera (RAS) or platelet-absorbed sera (PAS). The RAS and PAS were as effective as the unabsorbed HIS in abrogating early rejection as assessed by renal function and promotion of long-term survival. The absorbed sera retained the capacity to block the mixed lymphocyte culture (MLC) between Lew and BN lymphocytes and to a lesser degree the MLC between Lew and BUF, WF, AUG, and ACI lymphocytes; however, strain specificity was clearly evident at high antiserum dilutions. Similarly, these absorbed sera retained the capacity to block the Fc receptor of BN lymphocytes, and this effect was completely strain specific. In contrast, hemagglutinating and cytotoxic antibodies eluted from platelets used for antiserum absorption did not react with Fc receptors as assessed by rabbit antisheep (IgG)-coated SRBC (EA) rosette formation. F(Ab')2 fragments of PAS also blocked EA rosettes. On the other hand, complement rosettes (EAC) were not inhibited by the HIS. The antibodies were therefore directed against the Fc receptor itself or a structure spatially or functionally closely related to it. Both the Fc receptors and the enhancing capacity of the antisera were strictly specific for the BN genotype. It is suggested that the anti-"Fc receptor" antibody could play an important role in the induction of enhancement by impairing host T-B collaboration as a result of its binding to graft allogeneic "Fc receptors" which appear to be analogous to the major histocompatibility complex (MHC)-coded Ia antigens of the mouse.
将超免疫的Lewis抗Brown-Norway（BN）血清（HIS）诱导移植到Lewis受体体内的（Lewis/BN）F1肾增强的能力，与用Brown-Norway（BN）红细胞吸收血清（RAS）或血小板吸收血清（PAS）吸收掉血凝性抗Ag-B抗体后的同一抗血清的能力进行了比较。通过肾功能评估以及促进长期存活情况来看，RAS和PAS在消除早期排斥反应方面与未吸收的HIS同样有效。吸收后的血清保留了阻断Lewis与BN淋巴细胞之间混合淋巴细胞培养（MLC）的能力，对Lewis与BUF、WF、AUG和ACI淋巴细胞之间的MLC阻断能力稍弱；然而，在高抗血清稀释度时，品系特异性明显可见。同样，这些吸收后的血清保留了阻断BN淋巴细胞Fc受体的能力，且这种效应完全具有品系特异性。相比之下，从用于抗血清吸收的血小板上洗脱下来的血凝性和细胞毒性抗体，通过兔抗羊（IgG）包被的SRBC（EA）玫瑰花结形成评估，未与Fc受体发生反应。PAS的F（Ab'）2片段也阻断了EA玫瑰花结。另一方面，HIS未抑制补体玫瑰花结（EAC）。因此，这些抗体是针对Fc受体本身或与其在空间或功能上密切相关的结构。Fc受体和抗血清的增强能力都对BN基因型具有严格的特异性。有人提出，抗“Fc受体”抗体可能通过与移植异体“Fc受体”结合，损害宿主T-B协作，从而在诱导增强反应中发挥重要作用，这些“Fc受体”似乎类似于小鼠主要组织相容性复合体（MHC）编码的Ia抗原。
